The Prognostic Role of Systemic Inflammatory Response Index in Surgically Treated Pancreatic Ductal Adenocarcinoma Patients

Year 2025, Volume: 9 Issue: 3, 612 - 618, 30.09.2025

Eda Çalışkan Yıldırım , Savaş Gökçek Mehmet Uzun , Faruk Recep Özalp , Tarkan Unek , Özgül Sağol , İlkay Tuğba Ünek

https://doi.org/10.30621/jbachs.1735985

Abstract

Background:
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy despite advances in treatment. The systemic inflammatory response index (SIRI), a composite marker of neutrophils, monocytes, and lymphocytes, has been proposed as a prognostic biomarker in various cancers. However, its role in resectable PDAC is not well established.
Methods:
This retrospective study analyzed 82 patients who underwent curative-intent surgery for PDAC between 2011 and 2021. Preoperative SIRI was calculated as (neutrophils × monocytes) / lymphocytes using blood counts obtained within one week before surgery. The optimal SIRI cut-off for overall survival (OS) prediction was determined using ROC analysis. Survival outcomes were assessed via Kaplan-Meier curves and Cox regression models.
Results:
The optimal SIRI cut-off was 1.36 (AUC: 0.738). Patients with SIRI ≤1.36 had significantly longer OS than those with SIRI >1.36 (42 vs. 22 months, p=0.013), including among early-stage patients. In multivariate analysis, SIRI >1.36 remained an independent predictor of poor OS (HR: 1.87, 95% CI: 1.08–3.21, p=0.023), along with age, ECOG status, and disease stage.
Conclusions:
Preoperative SIRI is an independent prognostic marker in resectable PDAC and may help identify high-risk patients who could benefit from intensified follow-up or additional therapeutic strategies. Prospective multicenter studies are warranted to validate these findings and integrate SIRI into clinical risk models.

Keywords

pancreatic ductal adenocarcinoma(PDAC), systemic inflammatory response index(SIRI), , prognostic factor , overall survival

Ethical Statement

Ethics Committee Approval: The study was approved by Ethics Board of Dokuz Eylul University (Decision number 2021/29-12). Informed consent is not required in retrospective studies due to legal regulations in our country.

Supporting Institution

none

Thanks

none

The Prognostic Role of Systemic Inflammatory Response Index in Surgically Treated Pancreatic Ductal Adenocarcinoma Patients

Abstract

References

• Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A: Cancer statistics, 2025. CA: A Cancer Journal for Clinicians 2025;75:10-45.
• Rawla P, Sunkara T, Gaduputi V: Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World journal of Oncology 2019; 10:10.
• Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, Burkhart RA, Rinkes I, Molenaar IQ, Cameron JL, et al: Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. Ann Surg 2019;269:1154-1162.
• Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010;140:883-899.
• Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B: Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Journal of the National Cancer Institute 2014;106:dju124.
• Proctor M, McMillan D, Morrison D, Fletcher C, Horgan P, Clarke S: A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. British journal of cancer 2012;107:695-699.
• Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, Liu L, Meng Z, Wang P, Chen Z: A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer 2016;122:2158-2167.
• Tang C, Zhang M, Jia H, Wang T, Wu H, Xu K, Ren T, Liang L: The systemic inflammation response index (SIRI) predicts survival in advanced non-small cell lung cancer patients undergoing immunotherapy and the construction of a nomogram model. Front Immunol 2024; 15:1516737.
• Wu Q, Zhao H: Prognostic and clinicopathological role of pretreatment systemic inflammation response index (SIRI) in gastric cancer: a systematic review and meta-analysis. World J Surg Oncol 2024;22:333.
• Xu L, Yu S, Zhuang L, Wang P, Shen Y, Lin J, Meng Z: Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients. Oncotarget 2017;8:34954-34960.
• Ding Y, Liu Z, Li J, Niu W, Li C, Yu B: Predictive effect of the systemic inflammation response index (SIRI) on the efficacy and prognosis of neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. BMC Surg 2024; 24:89.
• Kim JS, Choi M, Kim SH, Hwang HK, Lee WJ, Kang CM: Systemic inflammation response index correlates with survival and predicts oncological outcome of resected pancreatic cancer following neoadjuvant chemotherapy. Pancreatology 2022; 22:987-993.
• Joyce JA, Pollard JW: Microenvironmental regulation of metastasis. Nature Reviews Cancer 2009;9:239-252.
• Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2002;2:161-174.
• Chanmee T, Ontong P, Konno K, Itano N: Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment. Cancers 2014;6:1670-1690.
• Man YG, Stojadinovic A, Mason J, Avital I, Bilchik A, Bruecher B, Protic M, Nissan A, Izadjoo M, Zhang X, Jewett A: Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J Cancer 2013;4:84-95.
• Jin Y, Christenson ES, Zheng L, Li K: Neutrophils in pancreatic ductal adenocarcinoma: bridging preclinical insights to clinical prospects for improved therapeutic strategies. Expert Review of Clinical Immunology 2024;20:945-958.
• Kiryu S, Ito Z, Suka M, Bito T, Kan S, Uchiyama K, Saruta M, Hata T, Takano Y, Fujioka S, et al: Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma. BMC Cancer 2021; 21:1197.
• Li S, Xu H, Wang W, Gao H, Li H, Zhang S, Xu J, Zhang W, Xu S, Li T, et al: The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma. Cancer Manag Res 2019;11:3327-3337.
• Shen H, Zuo F: Prognostic role of systemic inflammation response index (SIRI) in patients with pancreatic cancer: a meta-analysis. Front Oncol 2024;14:1465279.
• Niu Z-h, Lin L, Peng H-y, Zheng X-z, Wang M-y, Sun F-x, Xu C-j: The prognostic value of systemic inflammation response index in digestive system carcinomas: a systematic review and meta-analysis. BMC Gastroenterology 2025;25:34.
• Pacheco-Barcia V, Mondéjar Solís R, France T, Asselah J, Donnay O, Zogopoulos G, Bouganim N, Guo K, Rogado J, Martin E, et al: A systemic inflammation response index (SIRI) correlates with survival and predicts oncological outcome for mFOLFIRINOX therapy in metastatic pancreatic cancer. Pancreatology 2020;20:254-264.
• Dâmaso S, Paiva R, Pinho I, Esperança-Martins M, Lopes Brás R, Melo Alvim C, Quintela A, Lúcia Costa A, Costa L: Systemic inflammatory response index is a prognostic biomarker in unresectable pancreatic adenocarcinoma and identifies patients for more intensive treatment. memo- Magazine of European Medical Oncology 2022;15:246-252.